Jafron Biomedical Co.,Ltd. (SHE:300529)
China
· Delayed Price · Currency is CNY 18.84
+0.13 (0.69%)
Mar 10, 2026, 11:54 AM CST
Jafron Biomedical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 14,488 | 22,720 | 17,755 | 24,741 | 42,653 | 54,196 | Upgrade
|
| Market Cap Growth | -31.01% | 27.96% | -28.23% | -41.99% | -21.30% | 80.19% | Upgrade
|
| Enterprise Value | 13,432 | 21,627 | 16,803 | 23,822 | 41,394 | 52,930 | Upgrade
|
| Last Close Price | 18.71 | 28.29 | 21.13 | 28.75 | 48.52 | 61.31 | Upgrade
|
| PE Ratio | 29.72 | 27.70 | 40.68 | 27.81 | 35.64 | 61.92 | Upgrade
|
| Forward PE | 26.45 | 20.91 | 20.46 | 14.20 | 31.28 | 53.74 | Upgrade
|
| PS Ratio | 7.11 | 8.49 | 9.24 | 9.93 | 15.94 | 27.78 | Upgrade
|
| PB Ratio | 4.23 | 6.81 | 5.63 | 6.89 | 12.61 | 19.13 | Upgrade
|
| P/TBV Ratio | 4.36 | 7.04 | 5.85 | 7.20 | 13.27 | 20.28 | Upgrade
|
| P/FCF Ratio | 25.04 | 27.85 | 26.52 | 60.65 | 59.91 | 90.27 | Upgrade
|
| P/OCF Ratio | 19.25 | 21.62 | 19.37 | 27.99 | 34.14 | 56.60 | Upgrade
|
| EV/Sales Ratio | 6.59 | 8.08 | 8.74 | 9.56 | 15.47 | 27.13 | Upgrade
|
| EV/EBITDA Ratio | 18.15 | 19.32 | 29.30 | 23.92 | 30.15 | 52.81 | Upgrade
|
| EV/EBIT Ratio | 22.71 | 21.67 | 34.79 | 25.71 | 31.27 | 54.82 | Upgrade
|
| EV/FCF Ratio | 23.21 | 26.51 | 25.10 | 58.40 | 58.14 | 88.16 | Upgrade
|
| Debt / Equity Ratio | 0.42 | 0.42 | 0.53 | 0.36 | 0.27 | - | Upgrade
|
| Debt / EBITDA Ratio | 1.93 | 1.23 | 2.90 | 1.28 | 0.67 | - | Upgrade
|
| Debt / FCF Ratio | 2.47 | 1.70 | 2.50 | 3.13 | 1.29 | - | Upgrade
|
| Net Debt / Equity Ratio | -0.31 | -0.28 | -0.36 | -0.36 | -0.46 | -0.56 | Upgrade
|
| Net Debt / EBITDA Ratio | -1.43 | -0.83 | -1.98 | -1.29 | -1.13 | -1.57 | Upgrade
|
| Net Debt / FCF Ratio | -1.82 | -1.14 | -1.70 | -3.14 | -2.18 | -2.62 | Upgrade
|
| Asset Turnover | 0.37 | 0.49 | 0.35 | 0.49 | 0.67 | 0.68 | Upgrade
|
| Inventory Turnover | 1.37 | 1.44 | 1.07 | 1.61 | 2.54 | 2.70 | Upgrade
|
| Quick Ratio | 3.69 | 3.10 | 3.49 | 3.91 | 7.21 | 5.44 | Upgrade
|
| Current Ratio | 4.26 | 3.63 | 3.99 | 4.59 | 7.91 | 6.01 | Upgrade
|
| Return on Equity (ROE) | 14.20% | 25.10% | 12.63% | 25.26% | 38.47% | 34.89% | Upgrade
|
| Return on Assets (ROA) | 6.64% | 11.42% | 5.51% | 11.33% | 20.61% | 21.13% | Upgrade
|
| Return on Invested Capital (ROIC) | 19.85% | 36.51% | 18.25% | 38.79% | 56.14% | 75.72% | Upgrade
|
| Return on Capital Employed (ROCE) | 12.20% | 21.60% | 10.20% | 19.70% | 29.90% | 33.50% | Upgrade
|
| Earnings Yield | 3.33% | 3.61% | 2.46% | 3.60% | 2.81% | 1.62% | Upgrade
|
| FCF Yield | 3.99% | 3.59% | 3.77% | 1.65% | 1.67% | 1.11% | Upgrade
|
| Dividend Yield | 4.21% | 2.83% | 1.89% | 2.33% | 1.85% | 1.08% | Upgrade
|
| Payout Ratio | 134.11% | 41.47% | 128.71% | 82.00% | 44.37% | 43.17% | Upgrade
|
| Buyback Yield / Dilution | 3.68% | 1.57% | 0.08% | 1.12% | 0.89% | -2.22% | Upgrade
|
| Total Shareholder Return | 7.90% | 4.40% | 1.97% | 3.45% | 2.74% | -1.14% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.